Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308571 | 0.94 | RXRA (0.53) | MAPTLMNASMN1; SMN2PPARGCYP4Z1 | |
| SCHEMBL27858533 | 0.92 | LMNA (0.50) | MAPTLMNASMN1; SMN2PPARGCYP4Z1 | |
| SCHEMBL30567635 | 0.88 | MAPT (0.58) | MAPTLMNASMN1; SMN2PPARGCYP4Z1 | |
| SCHEMBL20351533 | 0.87 | MAPT (0.48) | MAPTLMNASMN1; SMN2PPARGCYP4Z1 | |
| SCHEMBL22541478 | 0.87 | CYP1A1 (0.45) | MAPTLMNASMN1; SMN2PPARGALDH1A1 | |
| SCHEMBL68851 | 0.85 | CYP4Z1 (0.62) | MAPTLMNASMN1; SMN2CYP4Z1POLB | |
| SCHEMBL12251326 | 0.84 | MAPT (0.74) | MAPTLMNASMN1; SMN2CYP4Z1POLB | |
| SCHEMBL7639131 | 0.83 | NPSR1 (0.54) | MAPTPPARGNPSR1KDM4EEPHX2 | |
| SCHEMBL5646521 | 0.83 | CYP4F2 (0.66) | MAPTPPARGCYP4Z1NPSR1KDM4E | |
| SCHEMBL26706628 | 0.83 | MAPT (0.44) | MAPTLMNASMN1; SMN2PPARGCYP4Z1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332276-A1 | Inhibitors of Molluscum Contagiosum Infection and Methods Using the Same | UNIV PENNSYLVANIA (US) | 2025-10-30 | — | — | US | disclosed |
| US-12454531-B2 | Substituted piperazine derivatives useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4587424-A1 | YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS | Bridgene Biosciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4529460-A1 | <SMALLCAPS/>? ? ?MOLLUSCUM CONTAGIOSUM? ? ? ? ?INHIBITORS OFINFECTION AND METHODS USING THE SAME | The Trustees of The University of Pennsylvania (US) | 2025-04-02 | — | — | EP | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024059317-A1 | YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS | BRIDGENE BIOSCIENCES, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | disclosed |
| WO-2023230472-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-11-30 | — | — | WO | disclosed |
| US-5977118-A | 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones and compositions and methods of use thereof | SANOFI (FR) | 1999-11-02 | — | — | US | disclosed |
| EP-0813527-A4 | 6-SUBSTITUTED PYRAZOLO 3,4-d] PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP INC (US) | 1998-09-09 | — | — | EP | disclosed |
| CN-1177960-A | 6-substituted pyrazolo (3, 4 -d) pyrimidin -4 ones and compositions and methods of use thereof | SANOFI WINTHROP INC (US) | 1998-04-01 | — | — | CN | disclosed |
| EP-0813527-A1 | 6-SUBSTITUTED PYRAZOLO 3,4-d] PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI PHARMACEUTICALS, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5656629-A | CYCLIC GUANOSINE MONOPHSPHATE-PHOSPHODIESTERASE INHIBITOR; USEFUL FOR TREATING HEART FAILURE AND/OR HYPERTENSION | SANOFI WINTHROP, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996028429-A1 | 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332276-A1 | Inhibitors of Molluscum Contagiosum Infection and Methods Using the Same | TBK1, EIF2AK2, ITCH | MAPT 1645/4885LMNA 3795/4885SMN1; SMN2 2980/4885 |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | MAPT 4030/4885LMNA 4345/4885SMN1; SMN2 2823/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | MAPT 4030/4885LMNA 4345/4885SMN1; SMN2 2823/4885 |
| US-12454531-B2 | Substituted piperazine derivatives useful as T cell activators | DGKZ, DGKA, DGKG | MAPT 4488/4885LMNA 3966/4885SMN1; SMN2 4621/4885 |
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | PRMT8, SIRT1, PRMT3 | MAPT 31/4885LMNA 1065/4885SMN1; SMN2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.